Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

WIB_icon

Flow Cytometry as a Prognostic Tool for Children With Down Syndrome and AML

The use of flow cytometry alone to determine measurable residual disease (MRD) status did not sufficiently identify children with acute myeloid leukemia (AML) and...

Treatment Delays and Hemostatic Abnormalities Predict Death in Newly Diagnosed APL

Major factors associated with early deaths in hospitalized patients with newly diagnosed acute promyelocytic leukemia (APL) included treatment delays and the incidence of hemostatic...

Oblimersen Shows No Added Benefit in Newly Diagnosed Acute Myeloid Leukemia

The addition of BCL-2 antisense oligonucleotide oblimersen to standard induction chemotherapy did not improve remission rates in older patients with newly diagnosed acute myeloid...
On location

Investigating the Combination of Ivosidenib Plus Venetoclax and Azacitidine in IDH-Mutated Myeloid Malignancies

In a small study of patients with IDH1-mutated myeloid malignancies, treatment with ivosidenib plus venetoclax, with or without azacitidine, had an acceptable safety profile and led to high...

Asparaginase Erwinia Chrysanthemi Approved for Leukemia/Lymphoma

Asparaginase Erwinia chrysanthemi (recombinant)-rywn has been approved by the FDA as part of a treatment regimen for adult and pediatric patients with acute lymphocytic...
On location

Venetoclax Added to Intensive Chemotherapy Is Safe, Effective in Relapsed/Refractory AML

In a study presented at EHA2021 Virtual, the annual congress of the European Hematology Association, adding short-term venetoclax to an intensive FLA-IDA chemotherapy regimen proved safe...
On location

First-in-Human Study Finds FF-10101-01 Has Clinical Activity in Relapsed/Refractory FLT3-Mutated AML

For patients with relapsed and/or refractory FLT3-mutated acute myeloid leukemia (AML), treatment with the selective and irreversible FLT3 inhibitor FF-10101-01 had promising clinical activity....
On location

Investigators Identify Distinct Molecular Subgroups to Guide Treatment Decisions in AML

Analyzing genetic data from more than 3,000 patients with acute myeloid leukemia (AML), researchers from Memorial Sloan Kettering Cancer Center identified 14 distinct molecular...

Post-Transplant MRD Monitoring With Non-DTA Mutations Predicts Outcomes in AML

In next-generation sequencing (NGS)-based measurable residual disease (MRD) monitoring, the use of non-DNMT3A, TET2, or ASXL1 (non-DTA) mutations may predict relapse and survival following...

Are Physician Perceptions of Transfusions a Barrier to Hospice Enrollment for Patients With AML?

Patients with acute myeloid leukemia (AML) and their caregivers generally defer end-of-life (EOL) transfusion decisions to clinicians without participating in shared decision-making. This tendency...